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Background: Metal oxide nanoparticles such as ZnO are used in sunscreens as they improve their optical
properties against the UV-light that causes dermal damage and skin cancer. However, the hazardous properties
of the particles used as UV-filters in the sunscreens and applied to the skin have remained uncharacterized.
Methods: Here we investigated whether different sized ZnO particles would be able to penetrate injured skin
and injured allergic skin in the mouse atopic dermatitis model after repeated topical application of ZnO particles.
Nano-sized ZnO (nZnO) and bulk-sized ZnO (bZnO) were applied to mechanically damaged mouse skin with or
without allergen/superantigen sensitization. Allergen/superantigen sensitization evokes local inflammation and
allergy in the skin and is used as a disease model of atopic dermatitis (AD).
Results: Our results demonstrate that only nZnO is able to reach into the deep layers of the allergic skin whereas
bZnO stays in the upper layers of both damaged and allergic skin. In addition, both types of particles diminish
the local skin inflammation induced in the mouse model of AD; however, nZnO has a higher potential to suppress
the local effects. In addition, especially nZnO induces systemic production of IgE antibodies, evidence of allergy
promoting adjuvant properties for topically applied nZnO.
Conclusions: These results provide new hazard characterization data about the metal oxide nanoparticles
commonly used in cosmetic products and provide new insights into the dermal exposure and hazard
assessment of these materials in injured skin.
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Nanotechnology is a rapidly developing area offering new
prospects in many industrial sectors. Metal oxides are one
of the most abundantly produced types of engineered
nanomaterials (ENM) with production volumes of up to
thousands of tons every year [1]. TiO2 and ZnO are well-
known and widely used metal oxides in many diverse
products, such as paints, coatings and cosmetics products
like sunscreens due to their opacifying, antimicrobial or
UV protective properties [2,3]. Nowadays it is estimated* Correspondence: harri.alenius@ttl.fi
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unless otherwise stated.that the total production volume of metal oxides being
used in the skin care market sector is about 2000 tons [4].
The increased utilization of these materials stems from
the problems associated with the bulk-sized inorganic
ingredients which were used in the older generations of
products. The poor dispersion quality, opaqueness and
comedogenic properties of non-nanoscale TiO2 and ZnO
have encouraged manufacturers to improve their products
by reducing the size of the particles [3,5]. Therefore sun-
screens are today one of the few nanomaterial-containing
products to which people are intentionally exposed [1].
Atopic dermatitis (AD) is a chronic inflammatory skin
disorder with a pathophysiology involving a complex
interaction between genetic and environmental factors. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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many as 2-10% of adults and up to 30% of children in
industrialized countries [7]. AD is highly pruritic relapsing
disease [8,9], that causes psychosocial distress and de-
creases significantly the quality of life of patients and their
families [10-12]. Furthermore, AD may progress to allergic
rhinitis and asthma over time, in a process called the
atopic march [13].
The pathomechanisms underpinning this inflammatory
skin disease are complex. The epidermal barrier dysfunc-
tion in AD is reported to be related to loss-of-function
mutations in the gene encoding (pro-)filaggrin which
increases the transepidermal water loss [9] and allows the
passive transfer of protein allergens [14]. A common fea-
ture of AD is the class switch from Th2 type immunity in
the acute phase toward Th1 during the chronic phase
[15]. In the acute phase of the disease, infiltration of T
cells and eosinophils [8] into the dermis can be observed
in parallel with release of Th2 type cytokines IL-4 and
IL-13 [16]. In contrast to the Th2 type environment
present in acute phase, Th1 cytokines such as IFN-γ
predominate in chronic skin lesions [15]. A deficiency
in the expression of antimicrobial peptides in inflamed
skin of AD patients contributes to the increased suscep-
tibility towards bacterial colonization of the skin [8]. In
particular, Staphylococcus aureus has been detected on the
skin of >90% of AD patients [17]. These bacteria release
exotoxins such as staphylococcal enterotoxin B (SEB) that
act as a superantigen, inducing T-cell activation and
triggering the release of pro-inflammatory, Th2 and Th1
type cytokines, thus aggravating and exacerbating the
disease [18-20].
Topical exposure to ENM, especially to TiO2 and
ZnO, and the penetration of the particles into the skin
has been investigated previously; however, the results of
the studies are somewhat controversial. Furthermore,
there is a lack of knowledge about the effects of these
materials on injured or diseased skin. When taking into
account the high prevalence of AD especially among
children, there is some concern about whether ENM can
cause health effects if the skin barrier integrity has been
is damaged. The aim of this study was to investigate the
effects caused by topically applied nano-sized ZnO
(nZnO) in the mouse model of AD and to compare
these outcomes to those induced by bulk-sized ZnO
(bZnO) to better understand the importance of ZnO
particle size.
Results
nZnO Particles penetrate through the sensitized skin in
the mouse model of atopic dermatitis
It has been postulated that particles are unable to pass
through intact skin but their ability to penetrate into
the damaged skin is unknown. The murine model of AD(Additional file 1) was used to study the particle penetra-
tion. In this model, a standardized skin injury is caused by
tape stripping thus mimicking the frequent scratching
which is commonly experienced by AD patients. Skin
samples were collected to investigate whether different
sized particles could be found in the different skin layers
in non-sensitized and OVA/SEB-sensitized mice. Both
materials were found in agglomerates on the skin surface.
The particles of nZnO, in contrast to bZnO, had a ten-
dency to accumulate more into hair follicles. Furthermore,
the presence of nZnO particles was detected in the epider-
mal and dermal layers of the skin of both PBS-treated and
OVA/SEB-challenged mice (Figure 1). Unlike in the skin
of vehicle-treated mice, the number of spectral matches of
nZnO in epidermis and dermis of AD-like skin lesions (i.e.
after OVA/SEB challenge) was remarkable, revealing par-
ticle accumulation especially in epidermal layer. In con-
trast to nZnO, bZnO was only detected on the surface of
both PBS-treated and OVA/SEB-challenged skin and no
particle penetration was detected into the epidermis and
dermis. This analysis suggests that AD-like skin enables at
least partial penetration of nZnO particles through the
damaged epidermis into the viable layers of the skin.
nZnO Treatment significantly reduces skin thickness in
the mouse model of atopic dermatitis
Patients with AD have an increased skin thickness and
inflammatory cell infiltratration into the inflamed skin
lesions. In the non-sensitized skin sites, the treatment
with ZnO particles did not cause any changes in the
thickness of skin layers whereas in the OVA/SEB-sensi-
tized skin, both the epidermal and dermal thicknesses
were reduced in ZnO-treated groups (Figure 2A). How-
ever, the reduction was statistically significant only in the
nZnO treated group compared to vehicle controls. These
results clearly demonstrate that nZnO reduced the skin
thickness in the allergic environment more efficiently
than bZnO.
nZnO Application significantly suppresses the influx of
inflammatory cells in allergic skin
T cells, eosinophils and mast cells are characteristic cell
types in AD skin. OVA/SEB sensitization significantly
increased infiltration of all inflammatory cells as compared
to non-sensitized mice skin (Figure 2B-K). bZnO and nZnO
significantly reduced the number of total inflammatory cells
and neutrophils in OVA/SEB-sensitized mice, and the num-
bers of these cells were significantly lower in nZnO-treated
mice skin as compared to bZnO (Figure 2B-C). Interest-
ingly, eosinophil numbers were significantly increased in
bZnO group compared to non-particle-treated and to
nZnO-treated OVA/SEB-sensitized mice (Figure 2D). In
contrast, the numbers of eosinophils were significantly
reduced in the skin of OVA/SEB-sensitized nZnO mice as
Figure 1 The morphology of nZnO (A) and bZnO (B) particles by TEM and their translocation into the skin after topical application.
TEM images of nZnO and bZnO materials reveal the differences in particle size and morphology. Scale bar 50 nm. Hyperspectral image analysis of
PBS (C), nZnO (D), bZnO (E), OVA/SEB sensitized (F), OVA/SEB and nZnO treated (G), and OVA/SEB and bZnO treated (H) skin sites. Images are
shown at 40x magnification, insets refer to the presence of particles in the skin or on its surface.
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tration was induced in all OVA/SEB-sensitized groups,
however, not as extensively in the nZnO-treated mice as
in the other groups (Figure 2E). Representative histological
features of the AD model after exposure to bZnO or
nZnO are shown in Figure 2F-K. These results indicate
that nZnO particles can suppress the infiltration of inflam-
matory cells more efficiently than bZnO particles in the
OVA/SEB-sensitized skin.
ZnO Particles diminish the infiltration of T-cells in
sensitized skin but induce the infiltration of macrophages
into damaged skin
Immunohistochemical stainings were performed to ana-
lyse different T-cell types and macrophages from sensi-
tized skin sites. The number of CD3+, DC4+ and CD8+
T-cells were significantly induced in the OVA/SEB-sensi-
tized mice skin whereas bZnO and nZnO treatments
reduced T-cell numbers in the OVA/SEB-sensitized skin
(Figure 3A-C, Additional file 2). Overall T-cell numbers
were lower in nZnO-treated mice than in the bZnO
group. In addition, macrophage numbers (F4/80+ cells)
were higher in the skin of particle-treated mice as com-
pared to non-particle-treated mice with an exception
of OVA/SEB-challenged and nZnO-treated group where
macrophage influx was insignificant in the comparison
with the OVA/SEB-sensitized group (Figure 3D, Additional
file 3). In the comparison of particle-treated skin samples,
it was noted that bZnO induced more extensive macro-
phage infiltration than nZnO. These results demonstrate
that ZnO particles reduce T-cell infiltration in OVA/SEB-
sensitized skin. However, macrophages are recruited to theparticle-treated tape-stripped skin, independently of the
sensitization status.
mRNA Expression of skin cytokines is downregulated in
nzno-treated mice
Lesional skin of AD patients exhibits increased expression
of pro-inflammatory, Th2 and Th1 cytokines [16,21]. The
levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF),
anti-inflammatory cytokine (IL-10), Th2-type cytokines
associated with allergy (IL-4, IL-13, IL-33) and Th1-type
cytokine (IFN-γ) were analysed from the treated skin sites
of all groups. Transcription of all studied cytokines was
induced by OVA/SEB sensitization. The mRNA levels
of pro-inflammatory cytokines were suppressed by ZnO
particle treatment (Figure 4A). The same phenomenon
was seen in IL-10 and IFN-γ mRNA levels (Figure 4B, D).
In addition, the expression of Th2-type cytokines was
significantly suppressed by nZnO but not by bZnO
(Figure 4C). Cytokine analysis demonstrates that nZnO
particles downregulated mRNA expression of different
types of cytokines whereas bZnO particle treatment did
not suppress Th2 type cytokines in the mouse model of
atopic dermatitis.
nZnO Suppresses the production of IL-13 and IFN-γ
cytokines in sensitized mice
Allergen (OVA) induced systemic production of major
Th1 and Th2 cytokines was investigated with circulating
lymphocytes from skin draining lymph nodes being har-
vested and stimulated with OVA. Production of IL-13 pro-
tein by lymph node cells collected from OVA/SEB-treated
mice was strongly induced after OVA stimulation; however,




















































































































Figure 2 (See legend on next page.)
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Figure 2 Thickness of epidermis and dermis, and the number of infiltrating cells on treated skin sites. A. Measurements were performed
from H&E-stained skin samples at 100x magnification. The light gray section in the columns represents epidermal and dark grey is the dermal
thickness. Statistical significances are indicated as * for epidermal thickness and # for whole skin thickness. **P < 0.01, #P < 0.05. The total inflammatory
cells (B), neutrophils (C), eosinophils (D) and mast cells (E) were counted after H&E at 1000x (B-D) and toluidine blue at 400x (E) and expressed as cells
per high power field (HPF). The columns and error bars represent means ± SEM (n = 8-16 mice per group). H&E-stained skin of PBS (F), bZnO (G), nZnO
(H), OVA/SEB sensitized (I), OVA/SEB and bZnO treated (J), and OVA/SEB and nZnO treated skin (K). Scale bar 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001.
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decreased after nZnO treatment but not in response to
bZnO treatment (Figure 5A). In addition, OVA stimulation
of cells collected from OVA/SEB-sensitized mice induced
IFN-γ protein secretion (Figure 5B). The amount of se-
creted IFN-γ protein was decreased when mice were
treated with ZnO particles and the reduction was greater
in response to nZnO application. However, the ZnO-
induced decrease in IFN-γ protein did not reach statistical
significance. These data suggest that topical treatment of
















































Figure 3 Distribution of T-cells and macrophages in treated skin sam
(D) cells were counted at magnification of 400x. The columns and error ba
**P < 0.01, ***P < 0.001.cytokine secretion also in draining lymph nodes stimulated
in vitro.
Local treatment with ZnO particles induces a systemic
increase in IgE antibody levels in sensitized mice
Patients with AD have elevated levels of total and allergen
specific IgE antibodies in the serum. In an attempt to
evaluate systemic effects of topical ZnO treatment, we
measured allergen (OVA)-specific IgG2a (Th1 surrogate),
IgE (Th2 surrogate) and IgG1 as well as superantigen
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Figure 4 Fold changes of mRNA levels of pro-inflammatory (A), anti-inflammatory (B), Th2-type (C), and Th1-type (D) cytokines in skin
biopsies of treated mice compared with PBS controls. Cytokine mRNA levels were measured by quantitative real-time PCR and normalized
























































Figure 5 Secretion of IL-13 and IFN-γ protein in lymph node cells re-stimulated with OVA in vitro after repeated topical application of
PBS and OVA/SEB with or without particle application. Cytokine levels were measured with ELISA. Bars represent means ± SEM (n = 4-8
pooled samples per group). **P < 0.01.
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after ZnO treatment in OVA/SEB-sensitized mice, and
nZnO induced the most significantly elevated response
(Figure 6A, B). In contrast, allergen induced OVA-specific
IgG1 levels in OVA/SEB-challenged mice were signifi-
cantly reduced after nZnO treatment (Figure 6C). There
were no significant differences in total or OVA-specific
IgG2a levels between the groups after topical treat-
ment of the mice (Additional file 4). SEB-specific IgG2a
or IgE levels did not reveal any differences between
treatment groups (data not shown). It is concluded
that local treatment with ZnO particles induced a sys-
temic increase in Th2 type antibody, IgE, in the mouse
model of AD.
Discussion
Sunscreens are widely used consumer products that may
contain nano-sized inorganic UV filtering agents such as
ZnO. The safety of ENM after topical application has
been evaluated using both in vitro and in vivo models
but the results emerging from the different studies are
controversial. Furthermore, there is a lack of data about
whether ENM can penetrate through damaged skin. Due
to the increasing prevalence of allergic skin conditions,
such as atopic dermatitis (AD), there is a need to under-
stand whether ENM may pose a hazard when applied
repeatedly onto injured and diseased skin. This study
investigated particle penetration and inflammatory effects
of nZnO and bZnO in compromised skin. We used a
mouse model of AD where the skin injury is inflicted by
tape stripping and the allergic skin condition is triggered
by application of two antigens, OVA and SEB. In order to
obtain similar dispersion quality and consistency as in
sunscreens, ZnO mixtures were prepared in this study
with the same nZnO content as allowed in commercial
products [22]. Furthermore, we decided to use repeated





































Figure 6 Antibody levels in mice sera after repeated topical applicati
without particle application. A. Total IgE values are shown as ratios com
IgG1 levels are shown as optical values measured at 405 nm. The columns
**P < 0.01, ***P < 0.001.fact that large numbers of people use sunscreens repeat-
edly on a daily basis [23].
Previously conducted studies performed on human
skin have reported conflicting penetration results after
epicutaneous exposure to nZnO. Studies on human vol-
unteers have shown that after a brief exposure to nZnO,
there is no penetration not only through viable healthy
skin but also through tape-stripped and lesional skin
[24]. However, after repeated application of nZnO on
healthy human skin, variable amounts of tracer 68Zn
could be detected in urine and a small amount in blood,
evidence of very low absorption of either soluble Zn,
ZnO particles or both [23,25]. The results of our study
showed that very small amounts of topically applied
nZnO could be detected in the upper layer of epidermis
and in openings of hair follicles of tape-stripped non-
allergic mouse skin. However, it has been reported that
material accumulation in follicular orifices does not pose
a risk as the particles remaining there are ultimately
removed by sebum flow [26]. Nonetheless, a significant
accumulation of nZnO particles in the epidermis and
lesser amount also into dermis was detected in the aller-
gic skin. In contrast to the situation with nZnO, bZnO
did not penetrate through either mechanically injured or
OVA/SEB-treated tissue. These results indicate that in-
flamed skin of AD patients might experience a notably
greater penetration and translocation of nZnO upon re-
peated application whereas the larger ZnO particles are
unable to reach into the deeper layers of the skin.
The thickened skin of AD lesions is accompanied by
the recruitment of inflammatory cells. In the acute lesions,
the dermal cellular infiltrate consists predominantly of
CD4+ T cells with some presence of eosinophils and mast
cells [27,28]. This phenomenon was also observed in our
study, confirming the functionality of the disease model.
Epicutaneous nZnO-treatment resulted in significantly




























on of vehicle, different sized ZnO particles, and OVA/SEB with or
pared to PBS-treated control, B. OVA-specific IgE and C. OVA-specific
and error bars represent means ± SEM (n = 8 mice /group).
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estingly, exposure to bZnO triggered a significant infiltra-
tion of eosinophils into the skin whereas nZnO slightly
inhibited their migration. Moreover, the infiltration of
macrophages was significantly increased especially in
response to topical bZnO treatment. In allergic skin,
nZnO significantly inhibited the recruitment of CD4+
and CD8+ T cells significantly. Taken together, these
results demonstrate that allergen induced skin inflam-
mation is significantly reduced, especially by the topical
exposure to nZnO particles. In contrast, exposure to
bZnO increases the infiltration not only of eosinophils
but also of macrophages into AD-like skin lesions.
To further explore the local effects of nZnO and bZnO
in the skin, we analysed several of the cytokines that are
involved in inflammatory processes of AD. Pro-inflam-
matory cytokines IL-1β, IL-6 and TNF are released in
response to mechanical injury and skin barrier disruption,
factors that are associated with scratching in AD [29,30].
In addition, the anti-inflammatory cytokine IL-10 is known
to be overexpressed in skin lesions of patients with AD
[31]. Furthermore, recent findings have revealed that
the expression of the Th2-promoting cytokine IL-33 is
elevated in AD skin after allergen or SEB exposure and
thatthis is followed by the production of IL-4 and IL-13
triggering Th2 lymphocyte differentiation [32]. It has
also been shown that superantigen exposure in AD skin
leads to the production of IFN-γ [19]. In our model of
AD, we determined similar cytokine expressions as de-
scribed in the literature. The expression levels of essen-
tially all cytokines were down-regulated when the mice
were treated with nZnO suggesting that the nZnO parti-
cles could suppress local inflammation whereas bZnO
failed to suppress Th2-type cytokine expression. We
also investigated allergen induced cytokine secretion
into the draining lymph nodes, in areas distant from the
site of the skin inflammation, and found that allergen
induced secretion was slightly, albeit not significantly,
suppressed, especially by the nZnO. The differences in
the local inflammation are probably seen due to the dif-
ferences in the particle size. As particle size decreases,
active surface area and particle reactivity increase [33].
In the water-dissolving ZnO particles, Zn2+ ions are re-
leased to a greaterextent from nZnO than bZnO [34]
and therefore the local effects are stronger if skin is
treated with nanoparticles (NP).
Very little is known about the inflammatory effects
of ZnO in the context of AD. While nZnO has not been
investigated in murine models of AD, the effects of
nano-sized TiO2 (nTiO2) have been described in vivo
[35]. However, instead of topical application, intradermal
administration of low dose of nTiO2 was used, assuming
that particles would be able to penetrate through the skin.
Yanagisawa et al. found that nTiO2 administration causesaggravation of AD lesions as reflected in elevated levels of
Th2-type cytokines in the skin. The results of our study
demonstrate that after repeated topical application of
nZnO in mice, the material reaches to the dermal layer of
AD-like skin but there is no penetration through mechan-
ically injured non-allergic tissue. In contrast to the effects
induced by nTiO2 [35], we found that nZnO could reduce
the skin thickness of antigen-sensitized mice and it sup-
pressed cell recruitment to inflammatory site. This was
further supported by the inhibition of the pro- and anti-
inflammatory, Th2- and Th1-type cytokines in AD-like
skin emphasizing the differences in chemical proper-
ties of these metal oxide NP. These findings demonstrate
that nZnO has a local anti-inflammatory effect on al-
lergic skin.
Patients suffering from AD are known to exhibit
elevated serum levels of total IgE and allergen-specific
IgE [36]. The present study revealed that total IgE and
specific IgE and IgG1 levels in serum were increased in
our murine model of AD. While specific IgG1 amounts
were reduced in allergic skin upon topical nZnO treat-
ment, the IgE levels, especially the levels of total IgE,
were notably enhanced when either of the materials,
nZnO or bZnO, were applied onto AD-like skin. The
observed effect was greater in response to nZnO treat-
ment than withbZnO. Thus, topical exposure, especially
to nZnO, could enhance the secretion of B-cell derived
IgE antibodies while it simultaneously dramatically sup-
presses allergen induced skin inflammation. It has been
reported that ZnO NP rapidlyrelease Zn2+ ions in phos-
phate buffer [34]. An earlier study conducted on human
volunteers where topical exposure of nZnO was investi-
gated by tracing 68Zn in blood and urine, concluded that
the detected levels of isotope might have been absorbed
as nZnO particles or as Zn2+ ions or possibly both [23].
For this reason, there remains the possibility that the
elevated IgE levels detected here might be caused by
non-specific reactions of released Zn2+ ions affecting IgE
production capabilities of the B-cells. The higher IgE
levels in nZnO-treated as compared to bZnO-exposed AD
mice could be explained by the increased release of Zn2+
ions from nZnO particles which first accumulated into
AD-like skin and ultimately the affected IgE production
capacity of the B-cells either in the draining lymph nodes
or in the spleen.
The underlying mechanisms of anti-inflammatory
(locally in the skin) or adjuvant properties (systemic
antibody production) of ZnO are still not fully understood
and further studies will beneeded. However, it can be spe-
culated that local concentrations of ZnO particles/Zn2+
ions in the skin are optimal for achieving anti-inflamma-
tory effects against allergen induced Th2 type skin inflam-
mation. In contrast, the substantially lower Zn2+ ion
concentration released into the circulation and further
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the major sources of antibody production), may be more
optimal for enhancing B-cell mediated IgE antibody pro-
duction. It should be also noted that the cell constituents
are very different in the skin compared to the lymphoid
organs. Thus, differences in the responding cells as well as
in concentrations of ZnO particles/Zn2+ ions may elicit
very different effects systemically and locally.
Conclusions
Our results demonstrate that after repeated topical expos-
ure to nZnO, the particles can reach to the dermal skin
layer of allergic skin. We also show that nZnO application
exerts anti-inflammatory properties by decreasing drastic-
ally local skin inflammation in the mouse model of AD.
However, clearly elevated systemic production of IgE anti-
bodies in allergic mice was detected in response to nZnO
application. Our data suggest that even though exposure
of AD patients to nZnO-containing sunscreens could have
a beneficial and symptom-relieving effect in the skin, cau-
tion is warranted when applying these products onto aller-
gic skin due to the possible aggravation of IgE-antibody
secretion. Furthermore, classical sunburns cause mechan-
ical damage and local irritation to the skin, and therefore
the skin’s protective barrier against NP may be diminished
in the very situation where sunscreens are commonly used
[37]. Nevertheless, when taking into account the elevated
risk for skin cancers, especially malignant melanoma,
without UV-protection, the use of sunscreens may well
outweigh the symptoms caused by application of nZnO-
containing creams. To conclude, this study provides
new information about the effects of nZnO applied
onto inflamed skin and in this way contributes to dermal
exposure assessment, exposure scenarios and hazard cha-
racterization of metal oxide ENM.
Materials and methods
Mice and sensitization
Female BALB/c mice (aged 6–8 weeks) were obtained
from Scanbur A/S (Karlslunde, Denmark) and quaran-
tined for one week. The mice were housed in groups of
four in transparent plastic cages bedded with aspen
chip and were provided with standard mouse chow
diet (Altromin no. 1314 FORTI, Altromin Spezialfutter
GmbH & Co., Germany) and tap water ad libitum when
not being treated. The environment of the animal room
was carefully controlled, with a 12 h dark–light cycle,
temperature of 20–21°C, and relative humidity of 40–45%.
The experiments were performed in agreement with the
European Convention for the Protection of Vertebrate
Animals Used for Experimental and Other Scientific
Purposes (Strasbourg March 18, 1986, adopted in Finland
May 31, 1990). All experiments were approved by the
State Provincial Office of Southern Finland.Mice (eight per group) were epicutaneously treated
with vehicle (PBS), bZnO particles, nZnO particles, a
combination of ovalbumin and staphylococcal entero-
toxin B (OVA/SEB, both purchased from Sigma-Aldrich
Co, St. Luis, MO), a combination of OVA, SEB and bZnO
or combination of OVA, SEB and nZnO under isoflurane
anesthesia (Univentor 400 Anesthesia Unit, Abbott
Laboratories, IL). The back of the mice was shaved with
an electronic razor and tape-stripped by adhesive tape to
induce a standardized skin injury. Stripping included
placing a piece of adhering tape onto shaved skin one to
four times, after which it was removed against the direc-
tion of the hair. The total amount of OVA was 100 μg and
SEB 2.5 μg/patch and the mass of bZnO or nZnO parti-
cles was 16.67 mg/patch (Additional file 1A). During the
first sensitization week, 100 μl of PBS or a mixture of
OVA/SEB in PBS was added to sterile gauze and then
secured onto the back skin with transparent adhesive tape.
After a two-week recovery period, the mice were again
tape-stripped and a new patch was secured onto the same
skin site. During the second sensitization week, ZnO ma-
terials were applied in PBS or OVA/SEB mixture. Patches
were applied twice during the first sensitization week and
three times during the second sensitization week. Mice
were killed by isoflurane overdose 24 h after the last
sensitization. Blood samples from the hepatic vein were
collected for antibody analysis, skin biopsies from treated
skin areas for RNA isolation and histology, and skin drain-
ing lymph nodes for re-stimulation with OVA or SEB to
analyse OVA and SEB induced secretion of cytokines
(Additional file 1B).
ZnO Particles and suspension preparation
bZnO was ordered from Camden-Grey Essential Oils, Inc
(Doral, FL) and nZnO from Nanostructured & Amorphous
Materials Inc (Houston, TX). The morphology and size of
the materials were characterised by transmission electron
microscopy (Jeol JEM 2010 TEM, Jeol Ltd., Tokyo, Japan)
as represented in Figure 1 and Additional file 5, respect-
ively. Samples were prepared from the ZnO powders by
crushing these gently, dispersing in ethanol and applying a
drop of the dispersion onto a copper grid-holey carbon
layer sample holder. The accelerating voltage used in TEM
was 200 kV. The material composition was determined
by energy dispersive spectroscopy EDS (ThermoNoran
Vantage, Thermo Scientific, Breda, The Netherlands
attached to Jeol JEM 2010 TEM). The elemental com-
position shown in Additional file 5 is the average of three
separate EDS analysis.
ZnO suspensions for experiments were prepared by
weighing the materials into glass tubes, dispersing in
PBS and water-bath sonicating for 20 minutes at 30°C.
Before application onto the patches, the suspensions were
diluted to 16.67 mg/ml in vehicle (PBS) or a mixture of
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their application onto the gauze patches.
Analysis of the translocation of ZnO particles in the skin
The CytoViva hyperspectral imaging microscopy system
(CytoViva, Inc, Auburn, AL) was used to analyse whether
bZnO and nZnO particles could penetrate into the skin in
the AD mouse model,. The essential parts of the hyper-
spectral imaging technology are a transmission diffraction
grating spectrograph and an integrated CCD camera that
are mounted onto the camera (C) mount of an Olympus
BX43 microscope (Olympus Corporation, Tokyo, Japan).
Hyperspectral images were captured, processed and
analysed in image analysis software CytoViva ENVI 4.8.
Sonicated 100 μg/ml ZnO dispersions in sterile PBS were
used for creating spectral libraries of the materials. Hy-
perspectral images of unstained 4-μm skin sections were
captured at 40x magnification. Images were normalized
and smoothened with the Savitski-Golay Curve Fit Smooth-
ing algorithm using a width of 11 bands. To exclude the
possibility for non-specific matches in images of material-
exposed tissue, spectral libraries of both ZnO materials
were filtered with spectra collected from PBS-treated and
OVA/SEB-challenged skin. Thereafter, Spectral Angle
Mapper Classification feature was used to find the loca-
tions of pixels matching the spectra of bZnO or nZnO in
the images of ZnO-treated skin.
Skin histology and immunohistochemistry
In the histological analysis, skin biopsies were fixed
in 10% buffered formalin and embedded in paraffin
and then 4-μm skin sections were cut and stained with
hematoxylin and eosin (H&E) for cell counts and to meas-
ure epidermal or dermal thicknesses, as well as with
o-toluidine blue for mast cell counts. In the immuno-
histochemical analysis, skin specimens were embedded
in Tissue-Tek oxacalcitriol compound (Sakura Finetek
Europe B.V., Zoeterwoude, The Netherlands) and frozen
quickly on dry ice. Staining of different subtypes of T-cells
(CD3+, CD4+ and CD8+) was conducted as described
earlier [19]. Briefly, the 4-μm skin samples were fixed
with cold acetone and stained using the ChemMate
(DakoCytomation, Glostrup, Denmark) staining kit. Pri-
mary anti-mouse monoclonal antibodies were obtained
from BD Pharmingen (San Diego, CA). Macrophages
(F4/80+) were stained in a similar technique with purified
rat anti-mouse F4/80 antibody (clone BM4007S, Acris
Antibodies, Herford, Germany). Biotin-conjugated secon-
dary antibodies were obtained from Vector Laboratories
Inc. (Burlingame, CA). The sections were examined under
light microscopy (Leica DM 4000B, Wetzlar, Germany).
Inflammatory cells were counted from 15 high-power
fields (HPF) at 1000x magnification, mast cells, T-cell
subtypes and macrophages at 400x magnification.Cytokine analysis by RT-PCR
Quantitative real-time reverse transcription-PCR analyses
were performed as previously described [19] with 7500
Fast Real-Time PCR system (Applied Biosystems, Foster
City, CA). Briefly, skin tissues were homogenized with
Ultra-Turrax T8 (IKA Labortechnik, Stafen, Germany) in
TRIsure® (Bioline GmbH, Luckenwalde, Germany). RNA
was isolated and extracted from skin tissues according
to TRIsure® instructions. The concentration of RNA was
measured with NanoDrop ND-100 Spectophometer
(Thermo Scientific, Wilmington, DE) and cDNA was syn-
thesized with High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). PCR primers and probes were
obtained from Applied Biosystems as pre-developed
reagents. The gene expression between different samples
was normalized to the 18S housekeeping gene. Results
are shown as fold change in comparison to vehicle-
treated mice.
Cytokine and antibody measurements by ELISA
Collected lymph nodes were mechanically ground and
LN cell suspensions from two mice were pooled (four
samples per group were analysed). The LN cell suspensions
were prepared in RPMI 1640 medium supplemented with
5% fetal bovine serum (FBS), 1% penicillin-streptomycin
(PEST), 1% non-essential amino acids (NEAA), 1 mM
sodium pyruvate, 10 mM HEPES (all obtained from
Invitrogen, Paisley, UK), 1% Ultraglutamine (Lonza,
Basel, Switzerland), and 0.05 mM 2-mercaptoethanol
(2-ME, Sigma-Aldrich Co, St. Luis, MO). Cells were cul-
tured in medium at 3 × 106 in 24-well plates in the pres-
ence of OVA (50 μg/ml) or SEB (1 μg/ml). The cell
culture medium was collected after 48 h of stimulation for
protein analysis. Mouse IL-13 and IFN-γ (eBioScience,
San Diego, CA) ELISAs were performed according to the
instructions given by the manufacturer.
Total and specific antibody levels were determined by
the ELISA method. The standard BD Pharmingen proto-
col for sandwich ELISA was used to quantify the total
amount of IgE and IgG2a in the sera. Purified mouse IgE
(clone R38-2) or IgG2a (clone G155-178) were used as
standards. 96-well plates were coated with rat anti-
mouse IgE mAb (clone R35-72) or anti-mouse IgG2a
mAb (clone R11-89), and bound IgE and IgG2a were
detected with biotin-conjugated rat anti-mouse IgE (clone
R35-118) or IgG2a (clone R19-15). Streptavidin-HRP and
peroxidase substrate reagents were used to generate the
color reaction. All reagents were ordered from BD Biosci-
ences (San Jose, CA) except for the peroxidase substrate
reagents which were from Kirkegaad & Perry Laboratories
(Gaithersburg, MD).
Serum levels of OVA specific IgE, IgG1 and IgG2, and
SEB specific IgE and IgG2a levels were measured by
the straight ELISA method. Briefly, 96-well plates were
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in 0.05 M NaHCO3 (pH 9.6) overnight (+4°C). The plates
were washed with 0.05% Tween20 in PBS, blocked with
3% bovine serum albumin (BSA) in PBS for 2 h (20°C)
and washed again. 100 μl of diluted sera (IgE: 1/60, 1/180,
1/540; IgG1: 1/2000, 1/20000, 1/200000; IgG2a: 1/60,
1/540, 1/1620) in 1% BSA in PBS was added and in-
cubated overnight (+4°C). After washing, 2 μg of biotin-
conjugated rat anti-mouse IgE (clone R35-118), IgG1
(clone A85-1) or IgG2a (clone R19-15) in 1% BSA in
PBS was added, incubated for 2 h (20°C) and washed.
Streptavidin-HRP (1/4000) in 1% BSA dissolved in PBS
was added and incubated for 30 min (20°C). After
washing, a mix of peroxidase substrate reagents was
added and absorbance read at 405 nm with a Labsystems
Multiscan MS-spectrophotometer (Thermo Scientific,
Wilmington, DE).
Statistics
All data are presented as means ± standard error, and
the difference between groups was analysed with Graph-
PadPrism 5 software (GraphPad Software, Inc. San Diego,
CA) using Student’s t-test or Mann–Whitney U-test. Dif-
ferences at P < 0.05 were considered to be statistically
significant.
Additional files
Additional file 1: Murine model of AD used in this study. In this
model, the back skin of mice was shaved and tape stripped one to four
times, mimicking skin injury inflicted by scratching in patients with AD.
100 μl of saline or a mixture of OVA and SEB in saline was placed on 1
cm2 patch of sterile gauze which was secured to the skin with a
transparent bioocclusive dressing (A). Each mouse had a total of five
exposures to the patch at the same site. Exposures were separated by
two-week interval and ZnO materials were applied during the second
sensitization week. Skin, blood and draining lymph nodes were collected
for different analyses (B).
Additional file 2: CD3, CD4 and CD8 stained skin of A. OVA/SEB,
B. OVA/SEB and bZnO, and C. OVA/SEB and nZnO treated skin.
Scale bar 100 μm.
Additional file 3: F4/80 stained skin of A. OVA/SEB, B. OVA/SEB and
bZnO, and C. OVA/SEB and nZnO treated skin. Scale bar 100 μm.
Additional file 4: Antibody levels in mice sera after repeated
topical application of vehicle, different sized ZnO, and OVA/SEB
with or without particle application. A. Total IgG2a values are showed
as ratios compared to PBS-treated control and whereas B. OVA-specific
IgG2a levels are showed as optical values measured at 405 nm. The
columns and error bars represent means ± SEM (n=8 mice /group).
**P<0.01.
Additional file 5: The physical identity of ZnO particles used in the
study.
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